In a milestone moment for Kenya’s healthcare landscape, AstraZeneca and the Aga Khan University Hospital, Nairobi (AKUHN) have announced a transformative partnership that will expand access to BRCA1/2 genetic testing—ushering in a new era of precision oncology for the region. For decades, AKUHN has stood as a regional benchmark for international-standard healthcare. Through this partnership, the hospital will now offer high-quality BRCA 1/2 testing at a significantly more accessible cost, reducing one of the biggest barriers to precision medicine in Africa. Prof. Shahin Sayed, Chair and Director of Laboratory Medicine at AKUHN, noted that diagnostics define outcomes. “Diagnostics are the backbone of healthcare… through this partnership, we will ensure patients who need precision diagnostics can access them without financial hardship.”